news
Therapeutic target for aggressive cancers discovered through CRISPR
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
List view / Grid view
Clinical Trials
news
Masitinib found to be an effective COVID-19 treatment in mouse model
Scientists from the University of Chicago discovered that the drug masitinib inhibits the replication of SARS-CoV-2 in mice.
whitepaper
Whitepaper: Buying a digital informatics system for your R&D?
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.
news
Promising new avenue to tackle obesity-related diabetes
New findings from collaborative research in the United States have identified a promising new treatment avenue for type 2 diabetes patients centring on the activity of the amino acid, GABA.
whitepaper
Infographic: A custom monoclonal antibody for your next project
Learn what sets Bethyl custom monoclonal antibodies quality and service apart and discover the top reasons why you should choose Forits Life Sciences for your next project.
webinar
Advantages of including untargeted and targeted metabolomics into drug development and clinical trials
25 May 2021 | By Metabolon
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
whitepaper
Article: Finding a (biomarker) needle in the haystack
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
article
COVID-19 in Europe – one year on from the first case
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.
article
Developing bioenergetic nanocatalysts, a novel approach to treat neurodegeneration
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
webinar
Novel small molecule inhibitors of oncogenic SHP2 variants characterised by cellular target engagement
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
news
Experimental antiviral AR-12 could be a promising COVID-19 treatment
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
article
Developing IL-15 superagonists for cancer therapy
Richard Sachse discusses how immunotherapies targeting interleukin 15 (IL-15) signalling can be optimised to enhance their efficacy and limit off-target effects.
article
Developing immunotherapies for hard-to-treat cancers
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
article
Pooling research and development resources to tackle emerging threats
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
news
New cancer treatment regimens could be identified with novel technology
A new technology called mass cytometry, or CyTOF, is providing new insights into a range of key proteins in blood cancer cells.